A 17-year-old is addressing hair loss with finasteride, topical minoxidil, and microneedling. They are considering adding GHK-Cu to their regimen, but others advise caution with finasteride due to age.
A 28-year-old shared surprising hair regrowth progress after 20 days using topical minoxidil, micro needling, GHK-cu, and BPC-157 injections. The user noted a significant reduction in their bald spot and overall hair improvement.
The conversation discusses hair thinning potentially linked to gut health issues and suggests biotin as a possible treatment. It also mentions that hair thinning could be due to male pattern baldness (MPB).
HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.
Trying out a new exosome treatment for male pattern baldness, in addition to increasing vitamin intake and using existing treatments such as Nizoral and scalp drops. The user has no expectations that the new treatment will work but is giving it a try anyway.
The user shares their experience with hair loss treatments, including oral finasteride, oral minoxidil, and a topical lotion for dandruff, expressing dissatisfaction with past treatments like PRP and hair transplants. They seek advice on a DNA test to determine suitable medications and express frustration with dermatologists' advice.
A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.
A 19-year-old male has been using topical finasteride and minoxidil for 8 months with no progress and is considering seeking a second opinion due to potential misdiagnosis. The discussion revolves around whether the hair loss is due to male pattern baldness, alopecia areata, or a vitamin deficiency.
Caffeine intake may increase DHT levels, but its impact on hair loss is minimal compared to genetic factors. Excessive caffeine can cause health issues, and its effects on hair loss are not directly applicable to humans based on rat studies.
Baldness is difficult to cure because current treatments like finasteride, dutasteride, and minoxidil only prevent hair shedding, and new developments are mostly ineffective. Botox shows potential in aiding skin regeneration and hair growth, but maintenance therapy with treatments like dutasteride and minoxidil may still be necessary.
Personal experience with Procyanidin B2 shows it's ineffective for hair loss. Viviscal Pro supplement tablets, containing Procyanidin B2, didn't help after 8 months of use.
The conversation discusses why DHT (dihydrotestosterone) negatively affects scalp hair but promotes growth elsewhere on the body. Various opinions include genetic predispositions, differences in hair follicle reactions to DHT, and the potential role of Omega-3 in reducing inflammation and promoting hair health.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.
Osteopontin, a protein involved in hair growth on moles, may help with hair loss. However, it is also linked to Alzheimer's, cancer, and bone development, so caution is advised.
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
Copper peptides, specifically GHK-Cu, are being considered for hair regrowth, though skepticism exists due to questionable product sources. Users suggest finding reputable sources for potential benefits, while acknowledging traditional treatments like Minoxidil and Finasteride.
17M approaching Norwood 2, using topical minoxidil and considering finasteride, oral minoxidil, and pyrilutamide. Plans to study dermatology and possibly get a hair transplant at 25 if treatments don't work.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
The user had four DHI hair transplants from 2021 to 2025 and is concerned about the lack of hair thickening despite using treatments like finasteride and minoxidil. They are seeking advice on why these efforts aren't working.
Sons offers free Biotin capsules, Thickening Clay, or Conditioner to UK men for hair care testing. Interested individuals can apply online to receive these products.
Hair loss theory suggests imbalance between Vitamin D Receptor (VDR) and Androgen Receptor (AR) activation. Proposed treatment includes upregulating VDR, downregulating AR, and improving mitochondrial health.
Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.
The user underwent a hair transplant in Boston, initially dissatisfied with the results, but later achieved significant improvement in hair density and natural appearance after consulting a different surgeon. They used finasteride, minoxidil, and low-level laser therapy as part of their treatment.
The user is concerned about the quick prescription process for hair loss treatments like Minoxidil and Finasteride through HIMs, questioning the lack of a thorough evaluation. Another user reassures that such practices are common, emphasizing the effectiveness and low risk of these treatments, and suggests monitoring personal response to the medication.
The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.